Odonate Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin Tang
- Full Time Employees
- 137
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4747 Executive Dr Ste 510 San Diego CA United States of America 10016
- IPO Date
- Dec 7, 2017
- CIK
- 0001717452
- Website
- odonate.com
- Similar Companies
- Business
- Odonate, Inc. (formerly Odonate Therapeutics, Inc.) operates as a shell company following the wind down of its pharmaceutical operations. Originally focused on developing oncology therapeutics, including tesetaxel, an orally administered chemotherapy agent from the taxane class for metastatic breast cancer patients; the company discontinued tesetaxel development in 2021 after FDA feedback indicated insufficient data for approval. Founded in 2013 and headquartered in New York, New York, Odonate previously conducted Phase III trials like CONTESSA and targeted patients requiring quality-of-life advantages over intravenous alternatives. In recent major changes, the company changed its name to Odonate, Inc. in March 2023, transitioned to OTC trading (ticker: ODTC) after Nasdaq delisting in January 2022 for public shell status, and implemented a 2021 share repurchase program for up to 20 million shares to return capital to shareholders amid operational cessation. No active product pipeline, partnerships, funding rounds, or expansions reported since 2021; current activities limited to shell company maintenance with approximately 145 employees listed.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Odonate Therapeutics Stock (ODT): Why The Price Plummeted Today
SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors
The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
ODT Stock Price Increases Over 20% Pre-Market: Details
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
3 Net Current Asset Value Stock Picks
Odonate Therapeutics (ODT) Enters Oversold Territory
Odonate Therapeutics: Lessons Learned
Odonate Therapeutics (ODT) is Oversold: Can It Recover?
Odonate Therapeutics Stock Price Increased 12.14%: Why It Happened
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?
ODT Stock Price Fell 79.19%: Why It Happened
Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations